Loading..

Heron Therapeutics, Inc. (HRTX) Report Analysis

Corporate Events

Positive

Heron Therapeutics, Inc.(NasdaqCM:HRTX) added t...

2022-06-24 00:00:00

Heron Therapeutics, Inc.(NasdaqCM:HRTX) added to Russell 3000E Growth Index

Positive

Heron Therapeutics, Inc.(NasdaqCM:HRTX) added t...

2022-06-24 00:00:00

Heron Therapeutics, Inc.(NasdaqCM:HRTX) added to Russell Microcap Growth Index

Positive

Heron Therapeutics, Inc.(NasdaqCM:HRTX) added t...

2022-06-24 00:00:00

Heron Therapeutics, Inc.(NasdaqCM:HRTX) added to Russell 3000E Index

Positive

Heron Therapeutics, Inc.(NasdaqCM:HRTX) added t...

2022-06-24 00:00:00

Heron Therapeutics, Inc.(NasdaqCM:HRTX) added to Russell Microcap Index

Neutral

Heron Therapeutics, Inc. Presents at 2022 Jeffe...

2022-05-26 20:05:00

Heron Therapeutics, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 08:30 AM. Venue: Marriott Marquis, New York City...

Neutral

Heron Therapeutics, Inc. Provides Revenue Guida...

2022-05-09 20:10:00

Heron Therapeutics, Inc. provided revenue guidance for the second quarter and full year 2022. Heron currently expects the second quarter of 20...

Neutral

Heron Therapeutics, Inc., Q1 2022 Earnings Call...

2022-05-03 20:05:00

Heron Therapeutics, Inc., Q1 2022 Earnings Call, May 09, 2022

Neutral

Heron Therapeutics, Inc. to Report Q1, 2022 Res...

2022-05-03 20:05:00

Heron Therapeutics, Inc. announced that they will report Q1, 2022 results on May 09, 2022

Neutral

Heron Therapeutics, Inc., Annual General Meetin...

2022-04-25 13:02:00

Heron Therapeutics, Inc., Annual General Meeting, May 24, 2022, at 09:00 Pacific Standard Time. Agenda: To consider to elect seven director no...

Neutral

Heron Therapeutics, Inc. Proposes Amendment in ...

2022-04-25 13:02:00

Heron Therapeutics, Inc. announced that the 2022 Annual Meeting of Stockholders will be held on May 24, 2022, To amend the Company's Certifica...

Neutral

Heron Therapeutics, Inc. - Shareholder/Analyst Call

2022-04-25 13:02:00

Annual Meeting of Stockholders

Neutral

Heron Therapeutics, Inc. Presents at Needham 21...

2022-04-05 20:05:00

Heron Therapeutics, Inc. Presents at Needham 21st Annual Healthcare Conference, Apr-11-2022 11:00 AM.

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare...

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New Yor...

Neutral

Needham & Company, LLC, Needham 21st Annual Hea...

2022-02-11 23:04:00

Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022.

Positive

Heron Therapeutics, Inc. Announces FDA Approval...

2021-12-09 13:00:00

Heron Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) ...

Neutral

Heron Therapeutics, Inc. - Special Call

2021-12-09 13:00:00

Heron Therapeutics, Inc. - Special Call

Positive

Heron Therapeutics Announces Submission of HTX-...

2021-11-18 12:30:00

Heron Therapeutics, Inc. announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for HTX-019...

Neutral

Heron Therapeutics, Inc. Presents at 12th Annua...

2021-11-12 03:07:00

Heron Therapeutics, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom.

Neutral

Heron Therapeutics, Inc. Presents at 4th Annual...

2021-11-11 21:05:00

Heron Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-01-2021 02:40 PM.

Neutral

Heron Therapeutics, Inc. Provides Sales Guidanc...

2021-11-03 20:01:00

Heron Therapeutics, Inc. provided sales guidance for the fourth quarter of 2021. For the quarter, the company expects fourth quarter of 2021 n...

Neutral

Heron Therapeutics, Inc. to Report Q3, 2021 Res...

2021-10-28 12:30:00

Heron Therapeutics, Inc. announced that they will report Q3, 2021 results on Nov 03, 2021

Neutral

Heron Therapeutics, Inc., Q3 2021 Earnings Call...

2021-10-28 12:30:00

Heron Therapeutics, Inc., Q3 2021 Earnings Call, Nov 03, 2021

Neutral

Heron Therapeutics, Inc. Presents at 2021 Veeva...

2021-10-13 14:20:00

Heron Therapeutics, Inc. Presents at 2021 Veeva R&D and Quality Summit Connect, Oct-14-2021 12:30 PM. Speakers: Susan Stamford, Executive Dire...

Positive

Heron Therapeutics, Inc. Announces Filing of Su...

2021-10-04 12:30:00

Heron Therapeutics, Inc. announced submission of a supplemental new drug application (NDA) for ZYNRELEF (bupivacaine and meloxicam) extended-r...

Negative

Heron Therapeutics, Inc. Announces Board Appointments

2021-09-24 12:30:00

Effective as of September 20, 2021, the Board of Directors of Heron Therapeutics, Inc. appointed Sharmila Dissanaike, M.D. to the Board, to se...

Neutral

Heron Therapeutics, Inc. Presents at Cantor Glo...

2021-09-21 20:05:00

Heron Therapeutics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 01:20 PM. Venue: New York, United States. Speakers:...

Neutral

Veeva Systems Inc., 2021 Veeva R&D and Quality ...

2021-09-14 11:03:00

Veeva Systems Inc., 2021 Veeva R&D and Quality Summit Connect, Oct 14, 2021.

Neutral

Heron Therapeutics, Inc. has filed a Shelf Regi...

2021-09-14 00:00:00

Heron Therapeutics, Inc. has filed a Shelf Registration in the amount of $26.202 million. Security Name: Common Stock Securities Offered: ...

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCO...

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Negative

Heron Therapeutics, Inc. Withdraws Sales Guidan...

2021-08-09 12:00:00

Heron Therapeutics, Inc. withdrawn sales guidance for the full year 2021. The company is withdrawing its full-year 2021 net product sales guid...

Neutral

Heron Therapeutics, Inc. Provides Sales Guidanc...

2021-08-09 12:00:00

Heron Therapeutics, Inc. provided sales guidance for the third quarter of 2021. The company currently expects third quarter of 2021 net produc...

Positive

Heron Therapeutics Announces Publication of Res...

2021-07-28 20:05:00

Heron Therapeutics, Inc. announced the results from the HOPE Hernia-1 study of ZYNRELEF (bupivacaine and meloxicam) in hernia repair surgery h...

Positive

Heron Therapeutics Announces Publication Showin...

2021-07-21 20:05:00

Heron Therapeutics, Inc. announced the online publication of new analysis evaluating the efficacy and safety of ZYNRELEF (bupivacaine and melo...

Neutral

Heron Therapeutics Announces 340B Prime Vendor ...

2021-07-06 12:30:00

Heron Therapeutics, Inc. announced that it has executed a contract for ZYNRELEF with Apexus, LLC (Apexus). Apexus is the designated Prime Vend...

Positive

Heron Therapeutics Announces U.S. Commercial La...

2021-07-01 12:30:00

Heron Therapeutics, Inc. announced ZYNRELEF (bupivacaine and meloxicam) extended-release solution, is now commercially available at all nation...

Positive

Heron Therapeutics, Inc.(NasdaqCM:HRTX) added to Russell 3000E Growth Index

2022-06-24 00:00:00

Heron Therapeutics, Inc.(NasdaqCM:HRTX) added to Russell 3000E Growth Index

Positive

Heron Therapeutics, Inc.(NasdaqCM:HRTX) added to Russell Microcap Growth Index

2022-06-24 00:00:00

Heron Therapeutics, Inc.(NasdaqCM:HRTX) added to Russell Microcap Growth Index

Positive

Heron Therapeutics, Inc.(NasdaqCM:HRTX) added to Russell 3000E Index

2022-06-24 00:00:00

Heron Therapeutics, Inc.(NasdaqCM:HRTX) added to Russell 3000E Index

Positive

Heron Therapeutics, Inc.(NasdaqCM:HRTX) added to Russell Microcap Index

2022-06-24 00:00:00

Heron Therapeutics, Inc.(NasdaqCM:HRTX) added to Russell Microcap Index

Neutral

Heron Therapeutics, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 08:30 AM

2022-05-26 20:05:00

Heron Therapeutics, Inc. Presents at 2022 Jefferies Global Healthcare Conference, Jun-08-2022 08:30 AM. Venue: Marriott Marquis, New York City, New York, United States.

Neutral

Heron Therapeutics, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2022

2022-05-09 20:10:00

Heron Therapeutics, Inc. provided revenue guidance for the second quarter and full year 2022. Heron currently expects the second quarter of 2022 net product sales for the oncology care franchise in the range of $22 million to $23 million.The company expects full-year 2022 net product sales for the oncology care franchise in the range of $89 million to $93 million.

Neutral

Heron Therapeutics, Inc., Q1 2022 Earnings Call, May 09, 2022

2022-05-03 20:05:00

Heron Therapeutics, Inc., Q1 2022 Earnings Call, May 09, 2022

Neutral

Heron Therapeutics, Inc. to Report Q1, 2022 Results on May 09, 2022

2022-05-03 20:05:00

Heron Therapeutics, Inc. announced that they will report Q1, 2022 results on May 09, 2022

Neutral

Heron Therapeutics, Inc., Annual General Meeting, May 24, 2022

2022-04-25 13:02:00

Heron Therapeutics, Inc., Annual General Meeting, May 24, 2022, at 09:00 Pacific Standard Time. Agenda: To consider to elect seven director nominees named in the accompanying proxy statement to serve until the 2023 annual meeting of stockholders and until their successors are duly elected and qualified; to ratify the appointment of Withum Smith+Brown, PC as independent registered public accounting firm for the year ending December 31, 2022; to approve compensation paid to named executive officers during the year ended December 31, 2021; to amend the company’s certificate of incorporation to increase the aggregate number of authorized shares of common stock by 100,000,000 from 150,000,000 to 250,000,000; to amend the company’s 2007 amended and restated equity incentive plan to increase the number of shares of common stock authorized for issuance thereunder from 27,800,000 to 30,700,000; and to transact other business.

Neutral

Heron Therapeutics, Inc. Proposes Amendment in Certificate of Incorporation

2022-04-25 13:02:00

Heron Therapeutics, Inc. announced that the 2022 Annual Meeting of Stockholders will be held on May 24, 2022, To amend the Company's Certificate of Incorporation to increase the aggregate number of authorized shares of common stock by 100,000,000 from 150,000,000 to 250,000,000.

Neutral

Heron Therapeutics, Inc. - Shareholder/Analyst Call

2022-04-25 13:02:00

Annual Meeting of Stockholders

Neutral

Heron Therapeutics, Inc. Presents at Needham 21st Annual Healthcare Conference, Apr-11-2022 11:00 AM

2022-04-05 20:05:00

Heron Therapeutics, Inc. Presents at Needham 21st Annual Healthcare Conference, Apr-11-2022 11:00 AM.

Neutral

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022

2022-02-14 21:00:00

Jefferies LLC, 2022 Jefferies Global Healthcare Conference, Jun 08, 2022 through Jun 10, 2022. Venue: Marriott Marquis, New York City, New York, United States.

Neutral

Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022

2022-02-11 23:04:00

Needham & Company, LLC, Needham 21st Annual Healthcare Conference, Apr 11, 2022 through Apr 14, 2022.

Positive

Heron Therapeutics, Inc. Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF

2021-12-09 13:00:00

Heron Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for ZYNRELEF (bupivacaine and meloxicam) extended-release solution to significantly expand the indication. ZYNRELEF is now indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures. ZYNRELEF is the first and only therapy for postoperative pain management to be rigorously tested in Phase 3 studies and demonstrate superiority to bupivacaine solution, the current standard-of-care. ZYNRELEF demonstrated superior, sustained postoperative pain relief for up to 72 hours and decreased the need for opioids, with more patients opioid-free compared to bupivacaine solution. With this approval, the FDA has confirmed that the superior efficacy demonstrated for ZYNRELEF in the pivotal trials supports its use in a broader group of related surgical procedures. This expanded indication for ZYNRELEF will now cover approximately 7 million procedures annually. The use of ZYNRELEF in the additional procedures offers surgeons the opportunity to further reduce their patients need for opioids following surgery, which can positively impact the patients and limit the postoperative discharge opioids that can lead to misuse. Postoperative opioids have been shown to be a doorway to addiction with over 2 million Americans becoming persistent opioid users after receiving opioids following surgery. Heron is continuing to study ZYNRELEF in additional procedures with plans to submit a second sNDA to the FDA in the second half of 2022 to support a broad indication for soft tissue and orthopedic surgical procedures, which is intended to cover the full 14 million target procedures.

Neutral

Heron Therapeutics, Inc. - Special Call

2021-12-09 13:00:00

Heron Therapeutics, Inc. - Special Call

Positive

Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA

2021-11-18 12:30:00

Heron Therapeutics, Inc. announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for HTX-019 (aprepitant) injectable emulsion for the prevention of postoperative nausea and vomiting (PONV) in adults. HTX-019 is a proprietary intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist (RA) that is approved for PONV prevention. The NDA filing includes data demonstrating the bioequivalence of HTX-019 32 mg as a 30-second IV injection to oral aprepitant 40 mg, supporting its efficacy for the prevention of PONV. Results also showed HTX-019 was well-tolerated with a similar safety profile compared to oral aprepitant. Because HTX-019 is administered as an IV injection, it provides convenient, rapid, consistent, and reliable exposure in all patients and overcomes the need to take the oral formulation 1 to 3 hours before anesthesia. The HTX-019 injectable emulsion formulation intended for PONV prevention is identical to the approved CINVANTI® (aprepitant) injectable emulsion formulation for prevention of chemotherapy-induced nausea and vomiting (CINV). Despite advances in postoperative care, nausea and vomiting has remained a challenge for many patients undergoing surgery. There are approximately 65 million diagnostic and surgical procedures at risk of resulting in PONV in the U.S. each year. More than half of these patients are at moderate to high risk of developing PONV. Recent data has also shown that PONV can lead to increases in medical costs and delays in discharge and recovery following procedures. Aprepitant is the first and only NK1 RA to be approved for prevention of PONV based on showing superiority to ondansetron, the current standard of care.

Neutral

Heron Therapeutics, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM

2021-11-12 03:07:00

Heron Therapeutics, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom.

Neutral

Heron Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-01-2021 02:40 PM

2021-11-11 21:05:00

Heron Therapeutics, Inc. Presents at 4th Annual Evercore ISI HealthCONx Virtual Conference, Dec-01-2021 02:40 PM.

Neutral

Heron Therapeutics, Inc. Provides Sales Guidance for the Fourth Quarter of 2021

2021-11-03 20:01:00

Heron Therapeutics, Inc. provided sales guidance for the fourth quarter of 2021. For the quarter, the company expects fourth quarter of 2021 net product sales for the oncology care franchise in the range of $20 million to $22 million.

Neutral

Heron Therapeutics, Inc. to Report Q3, 2021 Results on Nov 03, 2021

2021-10-28 12:30:00

Heron Therapeutics, Inc. announced that they will report Q3, 2021 results on Nov 03, 2021

Neutral

Heron Therapeutics, Inc., Q3 2021 Earnings Call, Nov 03, 2021

2021-10-28 12:30:00

Heron Therapeutics, Inc., Q3 2021 Earnings Call, Nov 03, 2021

Neutral

Heron Therapeutics, Inc. Presents at 2021 Veeva R&D and Quality Summit Connect, Oct-14-2021 12:30 PM

2021-10-13 14:20:00

Heron Therapeutics, Inc. Presents at 2021 Veeva R&D and Quality Summit Connect, Oct-14-2021 12:30 PM. Speakers: Susan Stamford, Executive Director, Clinical Business Operations.

Positive

Heron Therapeutics, Inc. Announces Filing of Supplemental New Drug Application for Significant Expansion of ZYNRELEF® Indication Statement Based on Successful Outcome of FDA Type C Meeting

2021-10-04 12:30:00

Heron Therapeutics, Inc. announced submission of a supplemental new drug application (NDA) for ZYNRELEF (bupivacaine and meloxicam) extended-release solution for an expanded indication. ZYNRELEF is currently indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty. At a recent Type C meeting with the U.S. Food and Drug Administration (FDA), the company gained agreement on the content of the supplement for expansion of the ZYNRELEF indication statement to include foot and ankle, small–to–medium open abdominal, and lower extremity total joint arthroplasty surgical procedures without the need for additional clinical studies. This submission is based on the consistent safety, efficacy and pharmacokinetic data from previously completed clinical trials. Alignment was also reached with the FDA on the data needed to support a future supplemental NDA to further expand the ZYNRELEF indication statement to broadly include soft tissue and orthopedic surgical procedures with pharmacodynamic, pharmacokinetic and safety data from a limited number of additional procedures. The studies in these additional surgeries are already in progress with the plan to submit the next supplement in the second half of 2022.

Negative

Heron Therapeutics, Inc. Announces Board Appointments

2021-09-24 12:30:00

Effective as of September 20, 2021, the Board of Directors of Heron Therapeutics, Inc. appointed Sharmila Dissanaike, M.D. to the Board, to serve an initial term ending with the 2022 Annual Meeting of Stockholders. Dr. Dissanaike has been University Distinguished Professor and Peter C. Canizaro Chair of the Department of Surgery at Texas Tech University Health Sciences Center (TTUHSC) since 2016. In addition, from 2015 to 2018, Dr. Dissanaike served as Interim Director of the Timothy J. Harnar Burn Center at University Medical Center in Lubbock, Texas (UMC). From 2014 to 2017, Dr. Dissanaike served as Trauma Medical Director of the John A. Griswold Level 1 Trauma Center at UMC. In January 2021, she was appointed to the Texas Medical Board by Governor Greg Abbott. Dr. Dissanaike is a clinically active trauma, burn and acute care surgeon who has won over 50 awards for clinical, academic and research excellence and service during her career. Dr. Dissanaike has published over 100 peer-reviewed scientific articles, in addition to numerous book chapters, peer-reviewed presentations and national and international invited lectureships. Dr. Dissanaike holds multiple national leadership and quality assurance roles including Chair of the American Burn Association Verification Committee, member of the American College of Surgeons Trauma Verification Committee and Committee on Trauma, and on the Boards of the American Burn Association and Southwestern Surgical Congress. She serves the American College of Surgeons as Governor and on the Committee for Ethics, the Advisory Council of Rural Surgery and Program Committee, highlighting her wide array of interests and longstanding dedication to advancing all aspects of surgical care. Effective as of September 20, 2021, the Board appointed Susan Rodriguez to the Board, to serve an initial term ending with the 2022 Annual Meeting of Stockholders. Ms. Rodriguez has served as Chief Commercial Officer of Ardelyx, Inc. since May 2020. Ms. Rodriguez has more than 25 years of experience in the biopharmaceutical industry, serving in senior commercial and operational management roles. From 2014 to 2019, Ms. Rodriguez served as the Chief Executive Officer of Tolmar Pharmaceuticals, Inc., a U.S. commercial specialty oncology company, for which in 2019, Ms. Rodriguez was named President of the branded division upon the formation of the global entity, Tolmar, Inc. At Tolmar, Ms. Rodriguez built out their U.S. specialty pharmaceutical business to become a market leader, which required establishing commercial presence in both 340B and private hospitals. Prior to Tolmar, from 1990 to 2014, Ms. Rodriguez held various positions of increasing responsibility at Abbott Laboratories (NYSE: ABT), most recently as Divisional Vice President of Global Marketing, where she led the global marketing function for an international portfolio of products. Prior to this role, Ms. Rodriguez served as the Vice President and General Manager of the Abbott Renal Franchise. Ms. Rodriguez received both a M.S. and B.S. in Psychology from the University of Pennsylvania. The Board has concluded that Ms. Rodriguez should serve as a director based on her experience in senior management and commercial operations with other biotechnology and pharmaceutical companies.

Neutral

Heron Therapeutics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 01:20 PM

2021-09-21 20:05:00

Heron Therapeutics, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-27-2021 01:20 PM. Venue: New York, United States. Speakers: Barry D. Quart, Chairman & CEO, John W. Poyhonen, President & Chief Commercial Officer.

Neutral

Veeva Systems Inc., 2021 Veeva R&D and Quality Summit Connect, Oct 14, 2021

2021-09-14 11:03:00

Veeva Systems Inc., 2021 Veeva R&D and Quality Summit Connect, Oct 14, 2021.

Neutral

Heron Therapeutics, Inc. has filed a Shelf Registration in the amount of $26.202 million.

2021-09-14 00:00:00

Heron Therapeutics, Inc. has filed a Shelf Registration in the amount of $26.202 million. Security Name: Common Stock Securities Offered: 2,200,000 Transaction Features: ESOP Related Offering

Neutral

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021

2021-08-24 20:29:00

Evercore Inc., 4th Annual Evercore ISI HealthCONx Virtual Conference, Nov 29, 2021 through Dec 03, 2021.

Negative

Heron Therapeutics, Inc. Withdraws Sales Guidance for the Full Year 2021

2021-08-09 12:00:00

Heron Therapeutics, Inc. withdrawn sales guidance for the full year 2021. The company is withdrawing its full-year 2021 net product sales guidance for the oncology care franchise based on the uncertainty associated with the rate of new cancer patient treatment starts and the impact of value-based contracting reimbursement.

Neutral

Heron Therapeutics, Inc. Provides Sales Guidance for the Third Quarter of 2021

2021-08-09 12:00:00

Heron Therapeutics, Inc. provided sales guidance for the third quarter of 2021. The company currently expects third quarter of 2021 net product sales for the oncology care franchise to increase approximately 5% to 10% compared to the prior quarter.

Positive

Heron Therapeutics Announces Publication of Results from HOPE (Helping Opioid Prescription Elimination), Showing ZYNRELEF™ Minimizes the Need for Opioids in a Real-World Setting, With 95% of Patients Experiencing an Opioid-free Recovery

2021-07-28 20:05:00

Heron Therapeutics, Inc. announced the results from the HOPE Hernia-1 study of ZYNRELEF (bupivacaine and meloxicam) in hernia repair surgery have been published online by Pain and Therapy in an article entitled, "Opioid-Free Recovery After Hernia Repair With HTX-011 as the Foundation of a Non-Opioid, Multimodal Analgesia Regimen in a Real-World Setting." In this study, ZYNRELEF, used with scheduled over-the-counter oral analgesics (acetaminophen and ibuprofen) and a personalized opioid prescription algorithm in a real-world environment, enabled more than 90% of patients to be discharged without an opioid prescription, with no callbacks for pain management and 95% of patients to recover opioid-free. ZYNRELEF is an extended-release solution of bupivacaine and meloxicam that is indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty. The study, HOPE Hernia-1, is part of the HOPE project, which is designed to provide surgeons with practical real-world solutions to effectively manage postoperative pain and eliminate the need for opioid prescriptions using ZYNRELEF as the foundation of a scheduled non-opioid multimodal analgesic regimen. ZYNRELEF contains an NSAID (non-steroidal anti-inflammatory drug), a type of medicine which: can increase the risk of a heart attack or stroke that can lead to death. This risk increases with higher doses and longer use of an NSAID. cannot be used during heart bypass surgery.can increase the risk of gastrointestinal bleeding, ulcers, and tears. ZYNRELEF should also not be used if are allergic to any components of ZYNRELEF, aspirin or other NSAIDs (such as ibuprofen or naproxen), or have had an asthma attack, hives, or other allergic reaction after taking any of these medicines; or as a paracervical block, during childbirth. The most common side effects of ZYNRELEF are constipation, vomiting, and headache. The medicines in ZYNRELEF (a local anesthetic and an NSAID) can affect the nervous and cardiovascular system; may cause liver or kidney problems; may reduce the effects of some blood pressure medicines; should be avoided if user have severe heart failure; may cause a rare blood disorder, or life-threatening skin or allergic reactions; may harm unborn baby if received at 20 weeks of pregnancy or later; and may cause low red blood cells (anemia).

Positive

Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF™

2021-07-21 20:05:00

Heron Therapeutics, Inc. announced the online publication of new analysis evaluating the efficacy and safety of ZYNRELEF (bupivacaine and meloxicam) extended-release solution in adults aged 65 years and older undergoing bunionectomy and hernia repair from the Phase 3 EPOCH 1 and EPOCH 2 studies. The analysis, published in the peer-reviewed journal Pain Management, showed that 58% of bunionectomy and 87% of hernia repair patients aged 65 years and older receiving ZYNRELEF required no opioids to manage their postoperative pain through 72 hours following surgery. Further, throughout the 72-hour period, the mean pain intensity never rose above the mild range. ZYNRELEF is an extended-release solution of bupivacaine and meloxicam that is indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty. In this post-hoc analysis, those 65 years and older who were administered ZYNRELEF used fewer opioids in bunionectomy and herniorrhaphy compared with bupivacaine (7.7 morphine milligram equivalents (MME) vs 15 MME, and 1.7 MME vs 3.5 MME, respectively). Importantly, a greater proportion of patients 65 years and older required no opioids (i.e., opioid-free) through 72 hours (58% vs 25%, and 87% vs 64%, respectively). ZYNRELEF was well tolerated in patients 65 years and older, with a safety profile similar to that forbupivacaine. The safety was also similar to patients aged younger than 65 years and to the overall populationsin the Phase 3 studies. No local anesthetic systemic toxicity events occurred and serious adverse events were rare with none considered related to ZYNRELEF.

Neutral

Heron Therapeutics Announces 340B Prime Vendor Contract with Apexus for ZYNRELEF™

2021-07-06 12:30:00

Heron Therapeutics, Inc. announced that it has executed a contract for ZYNRELEF with Apexus, LLC (Apexus). Apexus is the designated Prime Vendor for the 340B Drug Pricing Program. ZYNRELEF was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2021 for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy and total knee arthroplasty. ZYNRELEF is the first and only extended-release dual-acting local anesthetic and has been clinically shown to better manage pain, including severe pain, compared to standard-of-care bupivacaine over 72 hours and to significantly reduce or eliminate opioid use in many patients following surgery. The 340B Drug Pricing Program provides drug discounts to hospitals and clinics serving vulnerable communities. The 340B Drug Pricing Program allows 340B healthcare providers to stretch limited federal resources to reduce the price of outpatient pharmaceuticals for patients and expand health services to the patients and communities they serve. Under the agreement, Heron and the Prime Vendor Program, managed by Apexus, will collaborate to lower drug pricing for participating covered entities. The two organizations are working together to assure that covered entities have access to safe and effective non-opioid postoperative pain management.

Positive

Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF for the Management of Postoperative Pain for up to 72 Hours

2021-07-01 12:30:00

Heron Therapeutics, Inc. announced ZYNRELEF (bupivacaine and meloxicam) extended-release solution, is now commercially available at all national wholesalers and the specialty distributors in the United States. ZYNRELEF was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2021, for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty. Heron's new acute care sales team has extensive operating room, postoperative pain, and hospital launch experience. Heron's commercial organization has a proven track record of hospital success through launch of CINVANTI in 2018. The team has been meeting with key customers and has executed contracts for ZYNRELEF with the two large group purchasing organizations, Vizient and Premier Inc. ZYNRELEF delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam. The synergy between bupivacaine and meloxicam in ZYNRELEF has resulted in patients experiencing significantly less pain, including severe pain, and significantly more patients requiring no opioids (opioid-free) after surgery as compared to bupivacaine solution, the current standard-of care. ZYNRELEF contains an NSAID (nonsteroidal anti-inflammatory drug), a type of medicine which: can increase the risk of a heart attack or stroke that can lead to death. This risk increases with higher doses and longer use of an NSAID. cannot be used during heart bypass surgery. can increase the risk of gastrointestinal bleeding, ulcers, and tears. ZYNRELEF should also not be used if users are allergic to any components of ZYNRELEF, aspirin or other NSAIDs (such as ibuprofen or naproxen), or have had an asthma attack, hives, or other allergic reaction after taking any of these medicines; or as a paracervical block, during childbirth. The most common side effects of ZYNRELEF are constipation, vomiting, and headache. The medicines in ZYNRELEF (a local anesthetic and an NSAID) can affect the nervous and cardiovascular system; may cause liver or kidney problems; may reduce the effects of some blood pressure medicines; should be avoided if users have severe heart failure; may cause a rare blood disorder, or life-threatening skin or allergic reactions; may harm unborn baby if received at 20 weeks of pregnancy or later; and may cause low red blood cells (anemia).

Fundamental Summary

Heron Therapeutics published concerning results on 2022-05-09. Their negative growth, and value factors indicate that the company is finding it increasingly difficult to produce impressive numbers. Typically, results like these translate into sustained negative momentum and strong downward pressure on stock price. We therefore gave Heron Therapeutics a total score of 59 out of 100 and a UNDERPERFORM recommendation.

Heron Therapeutics reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported net loss was USD 63.89 million compared to USD 52.61 million a year ago. Basic loss per share from continuing operations was USD 0.63 compared to USD 0.58 a year ago.

Business Description

Heron Therapeutics, a biotechnology company, engages in developing treatments to address unmet patient needs. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics in January 2014. Heron Therapeutics was founded in 1983 and is headquartered in San Diego, California.

Sector Overview

Heron Therapeutics is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Heron Therapeutics's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.

Fundamental Highlights


Parameter Value Change Score
Assets 273.7 -10.5% 65
Liabilities 249.8 9.5% 84
Price to Book 12.4 3.0% 58
Cash & Equivalents 56.9 -37.1% 43
Equity 24.0 -69.1% 48
EBITDA -222.2 -5.3% 60
Total Revenues 89.8 4.0% 61
Parameter Value Change Score
Return on Equity -210.7 -49.9% 75
Net Cashflow -2.8 80.6% 66
Capital Expenditure -3.2 -6.8% 61
Asset Turnover 0.3 17.3% 84
Free Cashflow -2.1 1.6% 74

* All values are TTM

The below chart reflects Heron Therapeutics's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Heron Therapeutics's peer average final assessment score stands on 62.0, Heron Therapeutics's score is 59.

  •  HRTX
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow Rating Final Assessment mc_sort Hidden
Exact Sciences Corporation 7.2B 47 62 56
Underperform
46
46 0 1
Dynavax Technologies Corporation 1.5B 63 67 68
Hold
64
64 1 1
Celldex Therapeutics, Inc. 1.3B 57 70 69
Hold
61
61 2 1
Vericel Corporation 1.1B 57 56 65
Underperform
53
53 3 1
Avid Bioservices, Inc. 959.5M 67 75 66
Hold
69
69 4 1
Sorrento Therapeutics, Inc. 747.5M 74 55 52
Hold
61
61 5 1
Catalyst Pharmaceuticals, Inc. 707.1M 75 77 87
Buy
84
84 6 1
Organogenesis Holdings Inc. 612.1M 60 69 75
Hold
64
64 7 1
CTI BioPharma Corp. 603.6M 54 59 56
Underperform
50
50 8 1
Immatics N.V. 538.7M 76 77 86
Buy
84
84 9 1
Agenus Inc. 520.5M 54 74 58
Underperform
57
57 10 1
Vaxart, Inc. 440.0M 53 68 65
Underperform
56
56 11 1
MiMedx Group, Inc. 391.5M 45 59 60
Underperform
45
45 12 1
Albireo Pharma, Inc. 362.9M 54 65 63
Underperform
55
55 13 1
AVEO Pharmaceuticals, Inc. 337.5M 66 74 95
Hold
78
78 14 1
Viridian Therapeutics, Inc. 293.2M 65 53 65
Underperform
56
56 15 1
DermTech, Inc. 165.3M 56 52 58
Underperform
47
47 16 1
Amgen Inc. 130.1B 69 78 81
Hold
77
77 17 1
Gilead Sciences, Inc. 78.0B 57 73 62
Underperform
60
60 18 1
Vertex Pharmaceuticals Incorporated 70.6B 78 75 71
Buy
79
79 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 73
Hold
72
72 20 1
BioNTech SE 34.0B 75 79 72
Buy
79
79 21 1
Seagen Inc. 32.9B 61 62 58
Underperform
57
57 22 1
Biogen Inc. 29.7B 76 70 66
Hold
74
74 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 54 80 85
Hold
69
69 24 1
Incyte Corporation 16.8B 83 73 84
Buy
86
86 25 1
BioMarin Pharmaceutical Inc. 15.4B 70 82 63
Hold
74
74 26 1
United Therapeutics Corporation 10.6B 76 82 93
Strong Buy
88
88 27 1
Neurocrine Biosciences, Inc. 9.3B 68 55 63
Underperform
60
60 28 1
Exelixis, Inc. 6.7B 70 81 87
Buy
81
81 29 1
Sarepta Therapeutics, Inc. 6.5B 58 78 93
Hold
73
73 30 1
Halozyme Therapeutics, Inc. 6.3B 74 82 75
Buy
81
81 31 1
Ionis Pharmaceuticals, Inc. 5.4B 62 86 89
Buy
79
79 32 1
Ascendis Pharma A/S 5.2B 68 54 62
Underperform
60
60 33 1
Alkermes plc 5.0B 62 62 92
Hold
69
69 34 1
Cytokinetics, Incorporated 4.1B 64 66 69
Hold
65
65 35 1
Novavax, Inc. 4.0B 77 75 60
Hold
74
74 36 1
Mirati Therapeutics, Inc. 3.8B 50 64 65
Underperform
52
52 37 1
Natera, Inc. 3.6B 54 52 58
Underperform
47
47 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 71 76 70
Hold
74
74 39 1
Amicus Therapeutics, Inc. 3.0B 56 58 85
Hold
61
61 40 1
PTC Therapeutics, Inc. 2.8B 51 73 72
Underperform
59
59 41 1
CureVac N.V. 2.6B 57 74 90
Hold
70
70 42 1
Fate Therapeutics, Inc. 2.4B 53 46 61
Underperform
45
45 43 1
Insmed Incorporated 2.4B 55 57 82
Underperform
58
58 44 1
ACADIA Pharmaceuticals Inc. 2.3B 63 58 72
Hold
61
61 45 1
Abgenix Inc. 2.1B 67 47 58
Underperform
45
45 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 55 66 67
Underperform
57
57 47 1
Xenon Pharmaceuticals Inc. 1.9B 61 56 89
Hold
64
64 48 1
ChemoCentryx, Inc. 1.8B 61 73 87
Hold
71
71 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 68 79 78
Hold
76
76 50 1
Iovance Biotherapeutics, Inc. 1.7B 63 71 77
Hold
68
68 51 1
Xencor, Inc. 1.6B 67 79 98
Buy
82
82 52 1
Emergent BioSolutions Inc. 1.6B 61 66 75
Hold
65
65 53 1
Myriad Genetics, Inc. 1.5B 52 96 59
Hold
66
66 54 1
Ligand Pharmaceuticals Incorporated 1.5B 56 69 84
Hold
65
65 55 1
Aurinia Pharmaceuticals Inc. 1.4B 52 70 84
Hold
62
62 56 1
Veracyte, Inc. 1.4B 57 55 82
Underperform
59
59 57 1
Sierra Oncology, Inc. 1.3B 80 61 52
Hold
68
68 58 1
Agios Pharmaceuticals, Inc. 1.2B 50 75 75
Hold
60
60 59 1
CareDx, Inc 1.2B 52 50 86
Underperform
54
54 60 1
IVERIC bio, Inc. 1.1B 50 70 64
Underperform
54
54 61 1
FibroGen, Inc. 1.0B 73 67 84
Hold
76
76 62 1
Syndax Pharmaceuticals, Inc. 1.0B 58 62 57
Underperform
54
54 63 1
MannKind Corporation 957.2M 57 61 66
Underperform
56
56 64 1
ImmunoGen, Inc. 946.1M 56 64 87
Hold
64
64 65 1
Merus N.V. 941.6M 70 54 71
Hold
64
64 66 1
Enanta Pharmaceuticals, Inc. 922.8M 60 75 66
Hold
65
65 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 61 77 94
Hold
75
75 68 1
Anavex Life Sciences Corp. 767.1M 61 75 72
Hold
67
67 69 1
Amarin Corporation plc 734.5M 55 63 55
Underperform
52
52 70 1
Northwest Biotherapeutics, Inc. 682.9M 65 79 85
Hold
77
77 71 1
Sangamo Therapeutics, Inc. 600.0M 48 76 91
Hold
65
65 72 1
Vanda Pharmaceuticals Inc. 598.8M 64 62 69
Hold
62
62 73 1
AnaptysBio, Inc. 586.3M 52 68 80
Hold
60
60 74 1
Geron Corporation 566.2M 60 78 77
Hold
70
70 75 1
Eagle Pharmaceuticals, Inc. 546.4M 75 78 73
Buy
79
79 76 1
Radius Health, Inc. 499.8M 54 82 57
Hold
61
61 77 1
Mersana Therapeutics, Inc. 449.1M 58 47 65
Underperform
50
50 78 1
Inovio Pharmaceuticals, Inc. 416.9M 46 72 71
Underperform
54
54 79 1
Affimed N.V. 415.0M 54 66 74
Underperform
59
59 80 1
ADMA Biologics, Inc. 396.6M 68 57 71
Hold
64
64 81 1
Arbutus Biopharma Corporation 388.2M 60 67 95
Hold
71
71 82 1
Intercept Pharmaceuticals, Inc. 386.3M 57 86 96
Hold
78
78 83 1
Zymeworks Inc. 324.7M 62 56 57
Underperform
54
54 84 1
Anika Therapeutics, Inc. 322.7M 64 77 63
Hold
73
73 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 51 69 77
Hold
61
61 86 1
Silence Therapeutics plc 313.4M 66 72 69
Hold
70
70 87 1
AC Immune SA 299.8M 68 70 68
Hold
68
68 88 1
Precigen, Inc. 299.1M 73 79 74
Buy
79
79 89 1
bluebird bio, Inc. 288.7M 50 96 83
Hold
78
78 90 1
Sutro Biopharma, Inc. 245.5M 61 56 74
Underperform
59
59 91 1
Rigel Pharmaceuticals, Inc. 187.5M 62 64 41
Underperform
52
52 92 1
MacroGenics, Inc. 184.6M 47 71 65
Underperform
53
53 93 1
Chimerix, Inc. 178.4M 49 65 83
Underperform
58
58 94 1
Gelesis Holdings, Inc. 111.5M 78 39 80
Hold
66
66 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 49 61 58
Underperform
56
56 96 1
INSYS Therapeutics, Inc. 3.2M 43 70 73
Underperform
55
55 97 1

Technical Analysis

When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Heron Therapeutics's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Heron Therapeutics's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 37.

Bearish 37
Close Price 3.07
52W Low 2.3
52W High 15.61
5D MA 3.24
50D MA 3.66
200D MA 7.59
MACD -0.12
RSI 11.9
STOCH 70.0

Balance Sheet Analysis

Several numbers from Heron Therapeutics's current balance sheet were concerning, in two areas in particular: Cash & Equivalents and Equity. Heron Therapeutics's management did a relatively poor job managing cash and cash equivalents, which now sit at 56.9 and represents a -37.1% change from the last reporting period. The company's cash and cash equivalents metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Consequently, their cash and cash equivalents movement received a grade of 43. Also, Heron Therapeutics published concerning equity metrics for this filing. In the current report, equity stood at 24.0, which represents a -69.1% change from the last report. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. This performance is significantly less impressive than its peers and competitors. Its equity movement component, therefore, received a grade of 48. That said, one metric, Liabilities, stood out as strongly positive. Heron Therapeutics is doing a good job of keeping its liabilities under control and growing intelligently. At filing, their liabilities were 249.8, representing 9.5% change from the previous period. These numbers show that management has successfully encouraged growth while managing liabilities, especially relative to their peers. These results statistically lead to positive movement in stock prices, so we rated its liabilities movement component 84. Therefore, it received a cautionary score of 58.

Parameter Value Change Score
Assets 273.7 -10.5% 65
Liabilities 249.8 9.5% 84
Price to Book 12.4 3.0% 58
Cash & Equivalents 56.9 -37.1% 43
Equity 24.0 -69.1% 48
* All values are TTM

The below chart describes Heron Therapeutics's performance as reflected on its balance sheet with respect to its peers. While Heron Therapeutics received a balance sheet score of 58, the average of its peers stands on 62.0.

  •  HRTX
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Book Value Momentum Balance Sheet mc_sort Hidden
Exact Sciences Corporation 7.2B 57 58 45 42 52 47 0 1
Dynavax Technologies Corporation 1.5B 52 69 54 38 76 63 1 1
Celldex Therapeutics, Inc. 1.3B 48 69 61 44 57 57 2 1
Vericel Corporation 1.1B 51 65 56 53 61 57 3 1
Avid Bioservices, Inc. 959.5M 75 61 61 58 72 67 4 1
Sorrento Therapeutics, Inc. 747.5M 89 71 50 97 73 74 5 1
Catalyst Pharmaceuticals, Inc. 707.1M 52 69 70 77 86 75 6 1
Organogenesis Holdings Inc. 612.1M 59 66 56 66 60 60 7 1
CTI BioPharma Corp. 603.6M 84 70 37 92 37 54 8 1
Immatics N.V. 538.7M 56 70 84 95 73 76 9 1
Agenus Inc. 520.5M 73 62 37 55 60 54 10 1
Vaxart, Inc. 440.0M 69 67 47 56 47 53 11 1
MiMedx Group, Inc. 391.5M 53 66 42 57 37 45 12 1
Albireo Pharma, Inc. 362.9M 48 65 42 58 62 54 13 1
AVEO Pharmaceuticals, Inc. 337.5M 76 68 61 78 60 66 14 1
Viridian Therapeutics, Inc. 293.2M 56 72 44 37 76 65 15 1
DermTech, Inc. 165.3M 76 72 51 52 43 56 16 1
Amgen Inc. 130.1B 72 68 86 53 62 69 17 1
Gilead Sciences, Inc. 78.0B 48 63 61 52 62 57 18 1
Vertex Pharmaceuticals Incorporated 70.6B 69 69 58 84 92 78 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 48 65 52 86 81 67 20 1
BioNTech SE 34.0B 75 69 64 97 73 75 21 1
Seagen Inc. 32.9B 59 68 55 43 66 61 22 1
Biogen Inc. 29.7B 57 72 92 50 76 76 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 50 66 46 44 61 54 24 1
Incyte Corporation 16.8B 71 72 95 82 79 83 25 1
BioMarin Pharmaceutical Inc. 15.4B 55 75 54 77 74 70 26 1
United Therapeutics Corporation 10.6B 61 74 58 60 88 76 27 1
Neurocrine Biosciences, Inc. 9.3B 67 69 55 51 78 68 28 1
Exelixis, Inc. 6.7B 53 66 57 84 81 70 29 1
Sarepta Therapeutics, Inc. 6.5B 68 69 49 41 58 58 30 1
Halozyme Therapeutics, Inc. 6.3B 59 68 65 72 85 74 31 1
Ionis Pharmaceuticals, Inc. 5.4B 59 68 58 43 67 62 32 1
Ascendis Pharma A/S 5.2B 51 70 85 94 54 68 33 1
Alkermes plc 5.0B 63 66 46 54 71 62 34 1
Cytokinetics, Incorporated 4.1B 49 79 42 76 62 64 35 1
Novavax, Inc. 4.0B 61 67 52 77 99 77 36 1
Mirati Therapeutics, Inc. 3.8B 53 66 57 48 42 50 37 1
Natera, Inc. 3.6B 73 65 43 95 42 54 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 72 71 63 65 73 71 39 1
Amicus Therapeutics, Inc. 3.0B 52 64 58 66 56 56 40 1
PTC Therapeutics, Inc. 2.8B 57 61 80 49 37 51 41 1
CureVac N.V. 2.6B 49 64 75 52 52 57 42 1
Fate Therapeutics, Inc. 2.4B 63 70 54 39 45 53 43 1
Insmed Incorporated 2.4B 49 65 45 46 63 55 44 1
ACADIA Pharmaceuticals Inc. 2.3B 83 65 55 91 55 63 45 1
Abgenix Inc. 2.1B 81 57 86 92 45 67 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 46 67 46 50 62 55 47 1
Xenon Pharmaceuticals Inc. 1.9B 48 69 53 45 70 61 48 1
ChemoCentryx, Inc. 1.8B 72 77 47 53 52 61 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 49 68 87 67 63 68 50 1
Iovance Biotherapeutics, Inc. 1.7B 52 74 72 87 45 63 51 1
Xencor, Inc. 1.6B 53 78 60 40 67 67 52 1
Emergent BioSolutions Inc. 1.6B 48 62 87 48 61 61 53 1
Myriad Genetics, Inc. 1.5B 51 62 51 43 57 52 54 1
Ligand Pharmaceuticals Incorporated 1.5B 75 63 61 49 52 56 55 1
Aurinia Pharmaceuticals Inc. 1.4B 51 67 59 41 47 52 56 1
Veracyte, Inc. 1.4B 64 68 54 66 51 57 57 1
Sierra Oncology, Inc. 1.3B 62 71 52 97 97 80 58 1
Agios Pharmaceuticals, Inc. 1.2B 50 66 52 38 48 50 59 1
CareDx, Inc 1.2B 54 67 52 39 51 52 60 1
IVERIC bio, Inc. 1.1B 50 67 46 48 48 50 61 1
FibroGen, Inc. 1.0B 79 87 49 82 56 73 62 1
Syndax Pharmaceuticals, Inc. 1.0B 85 68 41 55 55 58 63 1
MannKind Corporation 957.2M 79 59 50 40 64 57 64 1
ImmunoGen, Inc. 946.1M 52 67 64 61 48 56 65 1
Merus N.V. 941.6M 59 68 50 83 81 70 66 1
Enanta Pharmaceuticals, Inc. 922.8M 51 86 45 38 49 60 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 56 71 38 82 63 61 68 1
Anavex Life Sciences Corp. 767.1M 50 67 50 75 66 61 69 1
Amarin Corporation plc 734.5M 51 65 58 72 51 55 70 1
Northwest Biotherapeutics, Inc. 682.9M 65 63 48 38 86 65 71 1
Sangamo Therapeutics, Inc. 600.0M 59 64 47 45 46 48 72 1
Vanda Pharmaceuticals Inc. 598.8M 82 70 47 89 56 64 73 1
AnaptysBio, Inc. 586.3M 85 63 41 37 51 52 74 1
Geron Corporation 566.2M 69 72 37 59 62 60 75 1
Eagle Pharmaceuticals, Inc. 546.4M 83 70 73 46 79 75 76 1
Radius Health, Inc. 499.8M 50 64 50 44 59 54 77 1
Mersana Therapeutics, Inc. 449.1M 75 68 39 82 52 58 78 1
Inovio Pharmaceuticals, Inc. 416.9M 56 66 38 54 40 46 79 1
Affimed N.V. 415.0M 56 66 63 56 47 54 80 1
ADMA Biologics, Inc. 396.6M 74 68 49 77 72 68 81 1
Arbutus Biopharma Corporation 388.2M 86 65 61 48 55 60 82 1
Intercept Pharmaceuticals, Inc. 386.3M 46 68 57 41 61 57 83 1
Zymeworks Inc. 324.7M 77 69 70 90 43 62 84 1
Anika Therapeutics, Inc. 322.7M 76 68 63 64 65 64 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 48 68 51 43 51 51 86 1
Silence Therapeutics plc 313.4M 58 71 69 63 59 66 87 1
AC Immune SA 299.8M 84 64 47 53 75 68 88 1
Precigen, Inc. 299.1M 81 85 61 72 48 73 89 1
bluebird bio, Inc. 288.7M 48 67 42 38 57 50 90 1
Sutro Biopharma, Inc. 245.5M 82 69 56 66 49 61 91 1
Rigel Pharmaceuticals, Inc. 187.5M 53 67 51 90 63 62 92 1
MacroGenics, Inc. 184.6M 53 64 61 37 39 47 93 1
Chimerix, Inc. 178.4M 48 63 46 95 40 49 94 1
Gelesis Holdings, Inc. 111.5M 47 76 48 76 98 78 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 37 71 45 39 55 49 96 1
INSYS Therapeutics, Inc. 3.2M 48 70 44 90 37 43 97 1

Income Statement Analysis

Heron Therapeutics appears likely to maintain its strong income statement metrics and momentum going forward. In this filing, Heron Therapeutics reported a return on equity (ROE) ratio of -210.7, which represents a change of -49.9%. The company appears headed in the right direction in terms of these return factors, exhibiting prudent capital expenditure growth compared to its peers. The company's return factors (ROA & ROE) components, therefore, received a grade of 75. Also, Heron Therapeutics reported highly encouraging numbers for its revenue efficiency. This parameter often affects companies in the same industry and market capitalization by up to 13.1%. Their impressive revenue efficiency is even more impressive relative to its peers and competitors in the current market. Consequently, their revenue efficiency received a grade of 61. That said, one metric, EBITDA, stood out as strongly negative. Heron Therapeutics reported concerning EBITDA this period. At filing, EBITDA was reported as -222.2, representing -5.3% change from the previous period. This metric might have a 24.4 percent impact on companies in the same industry and with the same market capitalization. Heron Therapeutics appears to be headed in the wrong direction in terms of EBITDA momentum, likely due to insufficient capital controls and a weaker than expected overall financial performance. Therefore, their EBITDA component earned a score of 60. Its income statement, therefore, earned a score of 62.

Parameter Value Change Score
EBITDA -222.2 -5.3% 60
Total Revenues 89.8 4.0% 61
Return on Equity -210.7 -49.9% 75
* All values are TTM

The below chart describes Heron Therapeutics's performance as reflected on its income statement with respect to its peers. While Heron Therapeutics received a income statement score of 62 , the average of its peers stands on 64.0.

  •  HRTX
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Return Factors Momentum Income Statement mc_sort Hidden
Exact Sciences Corporation 7.2B 57 67 54 62 0 1
Dynavax Technologies Corporation 1.5B 51 69 77 67 1 1
Celldex Therapeutics, Inc. 1.3B 96 53 78 70 2 1
Vericel Corporation 1.1B 76 44 82 56 3 1
Avid Bioservices, Inc. 959.5M 49 82 69 75 4 1
Sorrento Therapeutics, Inc. 747.5M 50 60 60 55 5 1
Catalyst Pharmaceuticals, Inc. 707.1M 48 88 58 77 6 1
Organogenesis Holdings Inc. 612.1M 89 55 79 69 7 1
CTI BioPharma Corp. 603.6M 84 50 62 59 8 1
Immatics N.V. 538.7M 37 93 53 77 9 1
Agenus Inc. 520.5M 57 83 45 74 10 1
Vaxart, Inc. 440.0M 99 51 72 68 11 1
MiMedx Group, Inc. 391.5M 87 43 83 59 12 1
Albireo Pharma, Inc. 362.9M 46 69 77 65 13 1
AVEO Pharmaceuticals, Inc. 337.5M 38 89 54 74 14 1
Viridian Therapeutics, Inc. 293.2M 55 50 63 53 15 1
DermTech, Inc. 165.3M 49 48 78 52 16 1
Amgen Inc. 130.1B 74 75 64 78 17 1
Gilead Sciences, Inc. 78.0B 78 71 52 73 18 1
Vertex Pharmaceuticals Incorporated 70.6B 57 80 62 75 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 67 74 66 74 20 1
BioNTech SE 34.0B 41 89 75 79 21 1
Seagen Inc. 32.9B 54 65 70 62 22 1
Biogen Inc. 29.7B 90 57 73 70 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 60 86 56 80 24 1
Incyte Corporation 16.8B 59 77 60 73 25 1
BioMarin Pharmaceutical Inc. 15.4B 72 81 65 82 26 1
United Therapeutics Corporation 10.6B 57 91 54 82 27 1
Neurocrine Biosciences, Inc. 9.3B 53 54 77 55 28 1
Exelixis, Inc. 6.7B 54 91 54 81 29 1
Sarepta Therapeutics, Inc. 6.5B 49 89 55 78 30 1
Halozyme Therapeutics, Inc. 6.3B 53 84 85 82 31 1
Ionis Pharmaceuticals, Inc. 5.4B 62 94 53 86 32 1
Ascendis Pharma A/S 5.2B 38 68 46 54 33 1
Alkermes plc 5.0B 69 55 81 62 34 1
Cytokinetics, Incorporated 4.1B 95 50 73 66 35 1
Novavax, Inc. 4.0B 41 89 54 75 36 1
Mirati Therapeutics, Inc. 3.8B 76 55 78 64 37 1
Natera, Inc. 3.6B 52 51 78 52 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 38 92 53 76 39 1
Amicus Therapeutics, Inc. 3.0B 61 55 77 58 40 1
PTC Therapeutics, Inc. 2.8B 54 78 66 73 41 1
CureVac N.V. 2.6B 45 83 71 74 42 1
Fate Therapeutics, Inc. 2.4B 45 52 61 46 43 1
Insmed Incorporated 2.4B 51 58 73 57 44 1
ACADIA Pharmaceuticals Inc. 2.3B 72 49 80 58 45 1
Abgenix Inc. 2.1B 47 47 47 47 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 41 74 72 66 47 1
Xenon Pharmaceuticals Inc. 1.9B 41 65 59 56 48 1
ChemoCentryx, Inc. 1.8B 97 57 71 73 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 70 79 61 79 50 1
Iovance Biotherapeutics, Inc. 1.7B 84 60 75 71 51 1
Xencor, Inc. 1.6B 42 94 52 79 52 1
Emergent BioSolutions Inc. 1.6B 91 51 77 66 53 1
Myriad Genetics, Inc. 1.5B 89 93 57 96 54 1
Ligand Pharmaceuticals Incorporated 1.5B 92 53 78 69 55 1
Aurinia Pharmaceuticals Inc. 1.4B 38 81 68 70 56 1
Veracyte, Inc. 1.4B 45 63 57 55 57 1
Sierra Oncology, Inc. 1.3B 84 54 54 61 58 1
Agios Pharmaceuticals, Inc. 1.2B 99 64 54 75 59 1
CareDx, Inc 1.2B 61 44 82 50 60 1
IVERIC bio, Inc. 1.1B 84 58 79 70 61 1
FibroGen, Inc. 1.0B 48 74 63 67 62 1
Syndax Pharmaceuticals, Inc. 1.0B 87 47 81 62 63 1
MannKind Corporation 957.2M 95 48 56 61 64 1
ImmunoGen, Inc. 946.1M 40 73 71 64 65 1
Merus N.V. 941.6M 48 60 59 54 66 1
Enanta Pharmaceuticals, Inc. 922.8M 90 63 72 75 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 60 79 70 77 68 1
Anavex Life Sciences Corp. 767.1M 84 69 60 75 69 1
Amarin Corporation plc 734.5M 95 44 82 63 70 1
Northwest Biotherapeutics, Inc. 682.9M 43 90 65 79 71 1
Sangamo Therapeutics, Inc. 600.0M 72 72 73 76 72 1
Vanda Pharmaceuticals Inc. 598.8M 89 46 81 62 73 1
AnaptysBio, Inc. 586.3M 97 50 77 68 74 1
Geron Corporation 566.2M 89 67 73 78 75 1
Eagle Pharmaceuticals, Inc. 546.4M 39 94 53 78 76 1
Radius Health, Inc. 499.8M 94 71 68 82 77 1
Mersana Therapeutics, Inc. 449.1M 37 54 72 47 78 1
Inovio Pharmaceuticals, Inc. 416.9M 96 57 68 72 79 1
Affimed N.V. 415.0M 95 49 75 66 80 1
ADMA Biologics, Inc. 396.6M 43 65 62 57 81 1
Arbutus Biopharma Corporation 388.2M 37 82 53 67 82 1
Intercept Pharmaceuticals, Inc. 386.3M 71 93 40 86 83 1
Zymeworks Inc. 324.7M 58 53 77 56 84 1
Anika Therapeutics, Inc. 322.7M 63 80 62 77 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 98 48 82 69 86 1
Silence Therapeutics plc 313.4M 83 64 69 72 87 1
AC Immune SA 299.8M 83 61 65 70 88 1
Precigen, Inc. 299.1M 57 87 59 79 89 1
bluebird bio, Inc. 288.7M 99 91 61 96 90 1
Sutro Biopharma, Inc. 245.5M 60 47 80 56 91 1
Rigel Pharmaceuticals, Inc. 187.5M 99 44 82 64 92 1
MacroGenics, Inc. 184.6M 95 56 74 71 93 1
Chimerix, Inc. 178.4M 99 50 62 65 94 1
Gelesis Holdings, Inc. 111.5M 41 46 56 39 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 83 49 92 61 96 1
INSYS Therapeutics, Inc. 3.2M 97 48 63 70 97 1

Cash Flow Analysis

Heron Therapeutics appears likely to maintain its strong cash flow metrics and momentum going forward. Heron Therapeutics is doing a remarkable job of keeping its asset turnover under control. At filing, their asset turnover metrics were 0.3, representing a 17.3% change from the previous period. This metric might have a 4.1 percent impact on companies in the same industry and with the same market capitalization. Their impressive asset turnover metrics, specifically in contrast to their industry peers' performance, should support a tailwind in the company's stock price. Therefore, its asset turnover movement earned a score of 84. Also, Heron Therapeutics's published free cash flow numbers were substantial and reflected management's focus on a healthy change strategy. Heron Therapeutics recorded free cash flow of -2.1, which represents a 1.6% change from the previous report. This parameter coud affect companies in the same industry and market capitalization by up to 2.6%. Their free cash flow situation is all the more impressive relative to their peers and competitors. Consequently, their free cash flow movement received a grade of 74. On the other hand, Capital Expenditure, jumped out as looking problematic. Heron Therapeutics's management did not a remarkable job this period managing capital expenditures (CapEx). In terms of the raw numbers, CapEx was reported as -3.2, which represents a -6.8% change from the last period. They appears to be headed in the wrong direction regarding resource allocation, exhibiting prudent capital expenditure growth compared to its peers. Therefore, their CapEx movement component earned a score of 61. Because the company's management is doing an excellent job managing these critical metrics, the cash flow was given a score of 71.

Parameter Value Change Score
Net Cashflow -2.8 80.6% 66
Capital Expenditure -3.2 -6.8% 61
Asset Turnover 0.3 17.3% 84
Free Cashflow -2.1 1.6% 74
* All values are TTM

The below chart describes Heron Therapeutics's performance as reflected on its cash flow with respect to its peers. While Heron Therapeutics received a cash flow score of 71, the average of its peers stands on 70.0.

  •  HRTX
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Capital Expenditure Growth Assets Factors Momentum Cash Flow mc_sort Hidden
Exact Sciences Corporation 7.2B 53 45 80 46 56 0 1
Dynavax Technologies Corporation 1.5B 64 48 82 65 68 1 1
Celldex Therapeutics, Inc. 1.3B 69 63 67 54 69 2 1
Vericel Corporation 1.1B 64 46 59 73 65 3 1
Avid Bioservices, Inc. 959.5M 80 38 40 50 66 4 1
Sorrento Therapeutics, Inc. 747.5M 48 63 61 52 52 5 1
Catalyst Pharmaceuticals, Inc. 707.1M 77 81 98 87 87 6 1
Organogenesis Holdings Inc. 612.1M 76 76 63 55 75 7 1
CTI BioPharma Corp. 603.6M 48 60 74 67 56 8 1
Immatics N.V. 538.7M 82 95 56 99 86 9 1
Agenus Inc. 520.5M 57 43 52 77 58 10 1
Vaxart, Inc. 440.0M 72 56 53 38 65 11 1
MiMedx Group, Inc. 391.5M 46 48 97 86 60 12 1
Albireo Pharma, Inc. 362.9M 59 68 41 95 63 13 1
AVEO Pharmaceuticals, Inc. 337.5M 94 87 74 83 95 14 1
Viridian Therapeutics, Inc. 293.2M 72 87 43 45 65 15 1
DermTech, Inc. 165.3M 60 51 45 86 58 16 1
Amgen Inc. 130.1B 80 74 67 74 81 17 1
Gilead Sciences, Inc. 78.0B 57 61 53 85 62 18 1
Vertex Pharmaceuticals Incorporated 70.6B 64 75 80 71 71 19 1
Regeneron Pharmaceuticals, Inc. 64.0B 69 86 64 66 73 20 1
BioNTech SE 34.0B 73 97 50 52 72 21 1
Seagen Inc. 32.9B 53 53 50 87 58 22 1
Biogen Inc. 29.7B 58 54 90 73 66 23 1
Alnylam Pharmaceuticals, Inc. 17.2B 82 80 70 89 85 24 1
Incyte Corporation 16.8B 78 79 92 74 84 25 1
BioMarin Pharmaceutical Inc. 15.4B 59 48 66 77 63 26 1
United Therapeutics Corporation 10.6B 93 92 68 80 93 27 1
Neurocrine Biosciences, Inc. 9.3B 63 43 54 74 63 28 1
Exelixis, Inc. 6.7B 79 90 89 83 87 29 1
Sarepta Therapeutics, Inc. 6.5B 85 89 95 87 93 30 1
Halozyme Therapeutics, Inc. 6.3B 83 66 52 49 75 31 1
Ionis Pharmaceuticals, Inc. 5.4B 88 96 60 86 89 32 1
Ascendis Pharma A/S 5.2B 48 59 77 98 62 33 1
Alkermes plc 5.0B 89 95 76 80 92 34 1
Cytokinetics, Incorporated 4.1B 63 79 89 51 69 35 1
Novavax, Inc. 4.0B 62 38 63 54 60 36 1
Mirati Therapeutics, Inc. 3.8B 56 58 71 89 65 37 1
Natera, Inc. 3.6B 52 54 56 84 58 38 1
Arrowhead Pharmaceuticals, Inc. 3.4B 60 39 87 96 70 39 1
Amicus Therapeutics, Inc. 3.0B 81 80 71 87 85 40 1
PTC Therapeutics, Inc. 2.8B 72 53 54 83 72 41 1
CureVac N.V. 2.6B 87 80 90 70 90 42 1
Fate Therapeutics, Inc. 2.4B 64 52 55 48 61 43 1
Insmed Incorporated 2.4B 79 80 61 89 82 44 1
ACADIA Pharmaceuticals Inc. 2.3B 61 57 98 80 72 45 1
Abgenix Inc. 2.1B 66 53 45 59 58 46 1
BioCryst Pharmaceuticals, Inc. 1.9B 61 58 54 96 67 47 1
Xenon Pharmaceuticals Inc. 1.9B 82 77 87 92 89 48 1
ChemoCentryx, Inc. 1.8B 84 92 97 50 87 49 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 66 67 76 78 50 1
Iovance Biotherapeutics, Inc. 1.7B 77 66 69 69 77 51 1
Xencor, Inc. 1.6B 96 95 70 95 98 52 1
Emergent BioSolutions Inc. 1.6B 70 53 87 75 75 53 1
Myriad Genetics, Inc. 1.5B 50 37 82 83 59 54 1
Ligand Pharmaceuticals Incorporated 1.5B 86 93 51 78 84 55 1
Aurinia Pharmaceuticals Inc. 1.4B 73 79 92 96 84 56 1
Veracyte, Inc. 1.4B 90 95 46 46 82 57 1
Sierra Oncology, Inc. 1.3B 47 77 38 71 52 58 1
Agios Pharmaceuticals, Inc. 1.2B 85 68 44 46 75 59 1
CareDx, Inc 1.2B 98 84 40 50 86 60 1
IVERIC bio, Inc. 1.1B 64 67 44 71 64 61 1
FibroGen, Inc. 1.0B 86 74 48 87 84 62 1
Syndax Pharmaceuticals, Inc. 1.0B 50 41 74 78 57 63 1
MannKind Corporation 957.2M 77 56 43 37 66 64 1
ImmunoGen, Inc. 946.1M 77 79 95 95 87 65 1
Merus N.V. 941.6M 70 71 74 53 71 66 1
Enanta Pharmaceuticals, Inc. 922.8M 58 47 84 83 66 67 1
Deciphera Pharmaceuticals, Inc. 914.0M 87 79 95 91 94 68 1
Anavex Life Sciences Corp. 767.1M 69 63 74 71 72 69 1
Amarin Corporation plc 734.5M 52 40 74 55 55 70 1
Northwest Biotherapeutics, Inc. 682.9M 80 77 81 86 85 71 1
Sangamo Therapeutics, Inc. 600.0M 85 78 93 83 91 72 1
Vanda Pharmaceuticals Inc. 598.8M 66 60 87 51 69 73 1
AnaptysBio, Inc. 586.3M 80 77 92 41 80 74 1
Geron Corporation 566.2M 78 68 49 81 77 75 1
Eagle Pharmaceuticals, Inc. 546.4M 63 40 97 92 73 76 1
Radius Health, Inc. 499.8M 64 40 37 56 57 77 1
Mersana Therapeutics, Inc. 449.1M 59 69 53 92 65 78 1
Inovio Pharmaceuticals, Inc. 416.9M 67 67 92 44 71 79 1
Affimed N.V. 415.0M 72 57 95 43 74 80 1
ADMA Biologics, Inc. 396.6M 62 77 74 85 71 81 1
Arbutus Biopharma Corporation 388.2M 92 93 80 87 95 82 1
Intercept Pharmaceuticals, Inc. 386.3M 87 95 98 89 96 83 1
Zymeworks Inc. 324.7M 52 65 45 83 57 84 1
Anika Therapeutics, Inc. 322.7M 69 67 70 51 63 85 1
Lexicon Pharmaceuticals, Inc. 321.6M 91 82 39 46 77 86 1
Silence Therapeutics plc 313.4M 68 66 72 69 69 87 1
AC Immune SA 299.8M 66 77 79 63 68 88 1
Precigen, Inc. 299.1M 82 75 37 85 74 89 1
bluebird bio, Inc. 288.7M 89 77 93 37 83 90 1
Sutro Biopharma, Inc. 245.5M 83 67 64 50 74 91 1
Rigel Pharmaceuticals, Inc. 187.5M 42 40 46 40 41 92 1
MacroGenics, Inc. 184.6M 70 53 54 46 65 93 1
Chimerix, Inc. 178.4M 80 84 95 47 83 94 1
Gelesis Holdings, Inc. 111.5M 64 90 92 98 80 95 1
Brooklyn ImmunoTherapeutics, Inc. 31.8M 58 72 43 71 58 96 1
INSYS Therapeutics, Inc. 3.2M 75 78 87 52 73 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.